ANL Utang marang Ekuitas Adlai Nortye Ltd

Logo korporat perusahaan Adlai Nortye Ltd (ANL)

Adlai Nortye Ltd. (ANL) is striving for global dominance in the small-molecule antineoplastic segment by promoting the drug buparlisib. This daily price chart reflects the dynamics of the separate_debt_total_eq metric, which stands at 0.11. The company relies on international alliances with medical centers to develop precision therapies; however, costly R&D and tensions between Washington and Beijing are undermining its financial stability.

ANL: Rasio Total Utang marang Ekuitas Adlai Nortye Ltd 21.02.2024 - 01.11.2026

Adlai Nortye - rincian analitis lan metrik utama (ANL)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Adlai Nortye Ltd|ANL - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Adlai Nortye|ANL - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Adlai Nortye|ANL - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku adlainortye.com|ANL - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Adlai Nortye Ltd.|ANL - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Adlai Nortye Ltd|ANL - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Adlai Nortye|ANL - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Adlai Nortye|Likuiditas cepet adlainortye.com
- informasi bathi lan kelipatan valuasi:
ANL - Bathi pungkasan
Pambiji fundamental perusahaan:Adlai Nortye Ltd., ANL
Barang utama Adlai Nortye Limited

Scaling Adlai Nortye Ltd. (ANL) within Asia's undersupplied oncology drug market requires significant resources; therefore, the degree of equity indebtedness reflects the balance between debt financing and shareholder equity. This metric measures financial leverage: excessive leverage increases default risk during liquidity disruptions, whereas moderate debt confirms the company's ability to invest effectively in expansion without compromising stability.

Analisis perusahaan pesaing

ONC (BeiGene) - Total Utang marang Modal|Total Utang marang Modal Halozyme Therapeutics, Inc.|Utang marang Ekuitas RevMed (RVMD)|Ascentage Pharma Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal CGON (CG Oncology, Inc.)|URGN - Rasio Total Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Utang marang Modal Personalis Inc|Erasca Corp (ERAS) - Utang marang Ekuitas|Delcath Corp - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas YMAB|AURA: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal CADL|Rasio Total Utang marang Ekuitas Accuray Inc ARAY|SELLAS Life Sciences Group - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Actuate Therapeutics Inc ACTU|CTOR - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi HURA (TuHURA Biosciences, Inc.)|TARA: Total Utang marang Modal|Utang marang Modal Fate Therapeutics Inc (FATE)|WHWK (Aadi Bioscience, Inc.) - Total Utang marang Modal|Total Utang marang Modal TScan|Total Utang marang Modal CSBR|xbiotech.com - Rasio Utang marang Ekuitas|Utang marang Ekuitas CEL-SCI CVM|OS Therapies Inc. - Utang marang Ekuitas|Radiopharm Theranostics Limited - Total Utang marang Modal|ARTV - Total Utang marang Modal|VERU: Total Utang marang Modal|TPST - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas XLO|RENB: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Mural Oncology plc (MURA)|kairospharma.com - Rasio Utang marang Ekuitas|Utang marang Ekuitas OnKure Therapeutics OKUR|CytoMed Therapeutics Ltd (GDTC) - Utang marang Modal|CRIS - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi APLM (Apollomics, Inc.)|THAR (Tharimmune Corp) - Rasio Total Utang marang Ekuitas|ADVB: Utang Agregat marang Modal|Rasio Total Utang marang Ekuitas GNPX|Utang marang Modal Calidi Bio CLDI|Total Utang marang Modal SBFM|XBIO - Utang marang Modal|Salarius - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi PPBT|AONC - Utang marang Ekuitas|BGNE: Utang marang Ekuitas|CKPT (Checkpoint Therapeutics, Inc.) - Rasio Total Utang marang Ekuitas|ELEV: Utang Agregat marang Modal|ICAD (iCAD Inc.) - Total Utang marang Modal|Rasio Utang marang Ekuitas IKNA (Ikena)|Rasio Total Utang marang Ekuitas NTBL (Notable Labs, Ltd.)|Koefisien Total Utang marang Modal viracta.com|Total Utang marang Modal MOR (MorphoSys)|Total Utang marang Modal NAYA Biosciences Inc NAYA|AAPGV - Utang marang Ekuitas